We are live on !
Find out more
Johnson & Johnson Portfolio holdings
AUM
$799M
Turnover
17.65%
1-Year Est. Return
253.51%
This Fund
S&P 500
This Quarter Est. Return
+4.85%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$334M
AUM Growth
-$7.78M
(-2.3%)
Cap. Flow
-$9
Cap. Flow % of AUM
Cap. Flow %
-0%
Top 10 Holdings %
Top 10 Hldgs %
97.27%
Holding
20
New
–
Increased
–
Reduced
1
Closed
–
Avg Time Held
2.8
years
Top 10 Avg Time Held
2.1
years
Top 20 Avg Time Held
2.7
years
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lyell Immunopharma
LYEL
|
+$9 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Protagonist Therapeutics
PTGX
$9.03B
| $136M | 40.83% |
2,449,183
| – | – |
2021 Q3
15 quarters
|
|
2
MeiraGTx Holdings
MGTX
$938M
| $43.9M | 13.14% |
6,641,064
| – | – |
2021 Q3
15 quarters
|
|
3
Rapport Therapeutics
RAPP
$1.27B
| $28.6M | 8.55% |
2,498,051
| – | – |
2024 Q2
4 quarters
|
|
4
Legend Biotech
LEGN
$3.68B
| $28.2M | 8.44% |
814,586
| – | – |
2021 Q3
15 quarters
|
|
5
Nanobiotix
NBTX
$1.49B
| $25.5M | 7.62% |
5,623,816
| – | – |
2023 Q3
7 quarters
|
|
6
CVRx
CVRX
$36.5M
| $23.9M | 7.15% |
4,103,430
| – | – |
2021 Q3
15 quarters
|
|
7
Procept Biorobotics
PRCT
$1.15B
| $20.4M | 6.1% |
357,939
| – | – |
2021 Q3
15 quarters
|
|
8
Contineum Therapeutics
CTNM
$316M
| $8.13M | 2.43% |
1,979,173
| – | – |
2024 Q2
4 quarters
|
|
9
Xencor
XNCR
$1.92B
| $6.09M | 1.82% |
748,062
| – | – |
2021 Q4
14 quarters
|
|
10
Arrowhead Research
ARWR
$8.24B
| $3.98M | 1.19% |
247,598
| – | – |
2021 Q3
15 quarters
|
|
11
Fate Therapeutics
FATE
$250M
| $3.51M | 1.05% |
3,379,064
| – | – |
2021 Q3
15 quarters
|
|
12
Neumora Therapeutics
NMRA
$76.2M
| $1.4M | 0.42% |
1,849,445
| – | – |
2023 Q3
7 quarters
|
|
13
Rallybio
RLYB
$87.1M
| $1.21M | 0.36% |
454,545
| – | – |
2024 Q2
4 quarters
|
|
14
Vor Biopharma
VOR
$1.12B
| $1.14M | 0.34% |
53,733
| – | – |
2021 Q3
15 quarters
|
|
15
Nano X Imaging
NNOX
$30.1M
| $831K | 0.25% |
158,852
| – | – |
2021 Q4
14 quarters
|
|
16
Standard BioTools
LAB
$251M
| $371K | 0.11% |
311,967
| – | – |
2024 Q1
5 quarters
|
|
|
17
Lyell Immunopharma
LYEL
$230M
| $368K | 0.11% |
41,165
-1
| -0% | -$9 |
2024 Q4
2 quarters
|
|
18
Adicet Bio
ACET
$40.1M
| $228K | 0.07% |
22,780
| – | – |
2021 Q3
15 quarters
|
|
|
HLSQ
19
Tessera Defense and Homeland Security Inc.
HLSQ
$2.45M
| $42.6K | 0.01% |
510
| – | – |
2021 Q3
15 quarters
|
|
20
Senseonics Holdings Inc
SENS
$391M
| $27K | 0.01% |
2,731
| – | – |
2021 Q3
15 quarters
|
|
Similar funds
Johnson & Johnson's Q2 2025 Portfolio in Review
As of Q2 2025, Johnson & Johnson held 20 positions worth $334M, down 2.3% from $342M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Trading was light in Q2 2025: portfolio turnover was 0%. Johnson & Johnson opened no new positions and made no exits, leaving the 20-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Johnson & Johnson's biggest Q2 2025 reduction was Lyell Immunopharma, cutting an estimated $9.
- Johnson & Johnson's ten largest holdings make up 97% of its $334M portfolio in Q2 2025.
- Johnson & Johnson opened 0 new positions and closed 0 in Q2 2025.
- Johnson & Johnson's portfolio value fell 2.3% quarter-over-quarter to $334M.
Based on Johnson & Johnson's 13F filing for Q2 2025, filed 22 Jul 2025.